IQVIA Holdings Inc. (NYSE:IQV) Receives $255.82 Average Target Price from Analysts

Shares of IQVIA Holdings Inc. (NYSE:IQV) have been given an average recommendation of “Moderate Buy” by the twenty-one ratings firms that are covering the stock, Marketbeat reports. Three analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $255.82.

A number of brokerages have commented on IQV. Truist Financial lowered their target price on IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a report on Thursday, December 12th. Stephens initiated coverage on IQVIA in a research report on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective for the company. Redburn Atlantic started coverage on shares of IQVIA in a research note on Monday, October 14th. They set a “buy” rating and a $276.00 price target on the stock. William Blair reissued an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Finally, Morgan Stanley lowered their target price on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a research note on Monday, November 4th.

IQVIA Stock Up 1.2 %

IQV stock opened at $197.39 on Wednesday. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The company’s 50 day simple moving average is $202.86 and its 200-day simple moving average is $222.01. IQVIA has a 12 month low of $187.62 and a 12 month high of $261.73. The firm has a market capitalization of $35.83 billion, a PE ratio of 25.90, a P/E/G ratio of 2.05 and a beta of 1.49.

Institutional Investors Weigh In On IQVIA

Institutional investors have recently bought and sold shares of the business. First Foundation Advisors lifted its holdings in shares of IQVIA by 3.8% during the 2nd quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock valued at $245,000 after acquiring an additional 43 shares in the last quarter. Invera Wealth Advisors LLC lifted its stake in shares of IQVIA by 0.3% during the second quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock worth $3,183,000 after purchasing an additional 46 shares in the last quarter. Private Trust Co. NA boosted its position in shares of IQVIA by 10.7% in the third quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock worth $115,000 after buying an additional 47 shares during the period. Oregon Public Employees Retirement Fund grew its stake in shares of IQVIA by 0.3% in the second quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock valued at $3,313,000 after buying an additional 48 shares in the last quarter. Finally, Clear Harbor Asset Management LLC raised its holdings in shares of IQVIA by 1.3% during the 3rd quarter. Clear Harbor Asset Management LLC now owns 3,969 shares of the medical research company’s stock valued at $941,000 after buying an additional 50 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.